Which of the following statements about the timing of RhoGAM administration is correct?

The correct statement regarding the timing of RhoGAM administration is that it is typically given at 28 weeks to all Rh-negative mothers. RhoGAM, which contains Rh immunoglobulin, is used to prevent Rh immunization in women who are Rh-negative and are carrying an Rh-positive baby. Administering RhoGAM at 28 weeks is a preventive measure to ensure that the mother’s immune system does not produce antibodies against Rh-positive blood cells that may enter her circulation from the fetus during pregnancy.

In addition to the 28-week administration, RhoGAM is also given after delivery if the newborn is confirmed to be Rh-positive. This provides further protection in case of any fetal blood cells that may enter the mother's bloodstream during or after delivery, but it is essential that the routine administration occurs at 28 weeks regardless of the immediate circumstances.

The other options do not align with the standard protocol for RhoGAM administration and guidance set forth by obstetric and medical organizations. Therefore, the focus on the timing at 28 weeks is a critical point in ensuring that Rh-negative mothers receive appropriate care throughout their pregnancy to mitigate potential Rh disease in future pregnancies.